Background There are no data on the effect of low‐dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …

Aim Apixaban is an oral factor X a inhibitor approved for stroke prevention in atrial fibrillation
and thromboprophylaxis in patients who have undergone elective hip or knee replacement …

Background Bleeding is a complication of treatment with factor Xa inhibitors, but there are no
specific agents for the reversal of the effects of these drugs. Andexanet is designed to …

Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …

Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …

Background New oral anticoagulants may simplify long‐term therapy by eliminating the
need for laboratory monitoring. Edoxaban is an oral, direct inhibitor of factor Xa that is given …

Study Objective The US Food and Drug Administration approval of the use of apixaban in
patients with a creatinine clearance (CrCl) of< 15 ml/minute or in those receiving dialysis is …

To provide direct comparison between apixaban and rivaroxaban in patients with acute
cancer‐associated venous thromboembolism (Ca‐VTE), consecutive patients treated with …

Background: Cancer patients receiving chemotherapy are at increased risk for thrombosis.
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …

Four target-specific oral anticoagulants (TSOA's) have been compared to a vitamin K
antagonist for the treatment of acute venous thromboembolism (VTE): dabigatran (D) …